Publications by authors named "Stanley Letovsky"

Introduction: The use of antibody titers against SARS-CoV-2, as a method of estimating subsequent infection following infection or vaccination, is unclear. Here, we investigate whether specific levels of antibodies, as markers of adaptive immunity, can serve to estimate the risk of symptomatic SARS-CoV-2 (re-) infection.

Methods: In this real-world study, laboratory data from individuals tested for SARS-CoV-2 antibodies under routine clinical conditions were linked through tokenization to a United States medical insurance claims database to determine the risk of symptomatic/severe SARS-CoV-2 infection outcomes.

View Article and Find Full Text PDF

The COVID-19 pandemic brought forth an urgent need for widespread genomic surveillance for rapid detection and monitoring of emerging SARS-CoV-2 variants. It necessitated design, development, and deployment of a nationwide infrastructure designed for sequestration, consolidation, and characterization of patient samples that disseminates de-identified information to public authorities in tight turnaround times. Here, we describe our development of such an infrastructure, which sequenced 594,832 high coverage SARS-CoV-2 genomes from isolates we collected in the United States (U.

View Article and Find Full Text PDF

Background: Understanding how allergies to 1 environmental fungus can lead to cosensitization to related fungi is important for the clinical management of allergies. Cosensitization can be caused by monosensitization combined with antibody cross-reactivity, or by coexposures driving independent sensitizations. A pioneering study showed that patterns of IgE cosensitization among 17 fungal species mirror fungal phylogeny.

View Article and Find Full Text PDF

Background: Many fungal species are associated with the pathogenesis of allergic disease, yet most epidemiologic studies on IgE-mediated fungal sensitization have only included a few species.

Objective: We investigated fungal allergen sensitization prevalence, risk factors, and geographic variation in the United States.

Methods: From 2014 to 2019, a total of 7,912,504 serum-specific IgE (sIgE) test results for 17 fungal species were measured in 1,651,203 patients aged 0-85 years by a US-wide clinical laboratory.

View Article and Find Full Text PDF

Myeloid neoplasms represent a broad spectrum of hematological disorders for which somatic mutation status in key driver genes is important for diagnosis, prognosis and treatment. Here we summarize the findings of a targeted, next generation sequencing laboratory developed test in 24,639 clinical myeloid samples. Data were analyzed comprehensively and as part of individual cohorts specific to acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).

View Article and Find Full Text PDF

Importance: In the absence of evidence of clinical utility, the United States' Centers for Disease Control and Prevention does not currently recommend the assessment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike-protein antibody levels. Clinicians and their patients, especially immunocompromised patients, may benefit from an adjunctive objective clinical laboratory measure of risk, using SARS-CoV-2 serology.

Objective: The aim of this study is to estimate the association between SARS-CoV-2 spike-protein targeted antibody levels and clinically relevant outcomes overall and among clinically relevant subgroups, such as vaccine and immunocompetency statuses.

View Article and Find Full Text PDF
Article Synopsis
  • Sero-surveillance of SARS-CoV-2 across 51 U.S. jurisdictions assessed infection-induced antibodies in over 1.4 million serum samples to understand undetected infections compared to reported cases.
  • The study found that seroprevalence increased significantly from 8% in November 2020 to 58% in February 2022, revealing that many infections were missed by traditional case reporting.
  • Notable disparities were observed in the ratios of seroprevalence to case prevalence, particularly during the spread of the Omicron variant and the availability of at-home testing, highlighting regional variations during winter 2021-2022.
View Article and Find Full Text PDF
Article Synopsis
  • - This study analyzed antibody concentrations in 3,067 COVID-19-unvaccinated individuals with detectable anti-SARS-CoV-2 antibodies, revealing significantly lower neutralizing and binding antibody levels compared to those seen after vaccination.
  • - Approximately 88% of participants had neutralizing antibody levels associated with 70% vaccine efficacy against symptomatic infection, but only about 30% had levels indicative of 90% vaccine efficacy; binding antibody levels were even lower.
  • - The findings underline the importance of vaccination for enhanced protection and recommend using standardized assays to measure antibody levels, which can inform public health decisions regarding booster doses, especially as new variants emerge.
View Article and Find Full Text PDF

Objective: An estimated 37 million Americans have chronic kidney disease (CKD). Nearly 90% do not know about their condition because of low awareness about the importance of CKD testing and diagnosis among practitioners and people at risk for CKD. This study uses data from a national clinical laboratory to identify guideline-recommended CKD testing rates across the U.

View Article and Find Full Text PDF

Background: This cross-sectional study aimed to track population-based SARS-CoV-2 antibody seropositivity duration across the United States using observational data from a national clinical laboratory registry of patients tested by nucleic acid amplification (NAAT) and serologic assays. Knowledge of antibody seropositivity and its duration may help dictate post-pandemic planning.

Methods: Using assays to detect antibodies to either nucleocapsid () or spike () proteins performed on specimens from 39,086 individuals with confirmed positive COVID-19 by reverse transcription-polymerase chain reaction (RT-PCR) from March 2020 to January 2021, we analyzed nationwide seropositivity rates of IgG up to 300 days following patients' initial positive NAAT test.

View Article and Find Full Text PDF

Next-generation sequencing (NGS) is widely used in genetic testing for the highly sensitive detection of single nucleotide changes and small insertions or deletions. However, detection and phasing of structural variants, especially in repetitive or homologous regions, can be problematic due to uneven read coverage or genome reference bias, resulting in false calls. To circumvent this challenge, a computational approach utilizing customized scaffolds as supplementary reference sequences for read alignment was developed, and its effectiveness demonstrated with two CBS gene variants: NM_000071.

View Article and Find Full Text PDF
Article Synopsis
  • Next-generation sequencing is making it easier to identify human genetic variations, but assessing the clinical significance of these variants—especially in BRCA1 and BRCA2 genes linked to breast and ovarian cancer—is increasingly challenging.* -
  • BRCA Share™ is a collaborative database developed by an alliance of academic centers and commercial testing labs, integrating mutation data with results from major testing services like Quest Diagnostics and LabCorp.* -
  • The database is primarily accessible for free to academic researchers, while commercial partners contribute data and pay fees that support ongoing curation and study of uncertain variants, showcasing successful collaboration between academia and industry.*
View Article and Find Full Text PDF

Purpose: We evaluated the Exome Aggregation Consortium (ExAC) database as a control cohort to classify variants across a diverse set of genes spanning dominant and recessively inherited disorders.

Methods: The frequency of pathogenic variants in ExAC was compared with the estimated maximal pathogenic allele frequency (MPAF), based on the disease prevalence, penetrance, inheritance, allelic and locus heterogeneity of each gene. Additionally, the observed carrier frequency and the ethnicity-specific variant distribution were compared between ExAC and the published literature.

View Article and Find Full Text PDF

Experimental data exists for only a vanishingly small fraction of sequenced microbial genes. This community page discusses the progress made by the COMBREX project to address this important issue using both computational and experimental resources.

View Article and Find Full Text PDF

We present a computational approach based on a local search strategy that discovers sets of proteins that preferentially interact with each other. Such sets are referred to as protein communities and are likely to represent functional modules. Preferential interaction between module members is quantified via an analytical framework based on a network null model known as the random graph with given expected degrees.

View Article and Find Full Text PDF

Motivation: The development of experimental methods for genome scale analysis of molecular interaction networks has made possible new approaches to inferring protein function. This paper describes a method of assigning functions based on a probabilistic analysis of graph neighborhoods in a protein-protein interaction network. The method exploits the fact that graph neighbors are more likely to share functions than nodes which are not neighbors.

View Article and Find Full Text PDF